ClinicalTrials.gg
RecruitingNCT06320132BLANDISHUpdated Nov 4, 2026

BLANDISH (Brain, Loss of Function, Aneurism, Disease, Injury, Stroke, Hemorrhage)

An observational study in Intracranial Hemorrhages, sponsored by IRCCS Ospedale San Raffaele. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by IRCCS Ospedale San Raffaele · Observational

How we know

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 8 months later.
Updated Nov 4, 2026Study contact changed1 site added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
2,000
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this observational study is to train a machine learning system based on data from patients affected by spontaneous Intracranial Hemorrage. The main question it aims to answer is whether there is a correlation between actual clinical pratice, reached outcomes and favorable or unfavorable predictive factors, and anamnesis.

Participants will be treated as per standard clinical practice.

Read the detailed description

In NeuroICU, treatments typically adhere to guidelines based on scientific consensus. Despite this, the prognosis for patients with intracranial hemorrhages has not significantly improved over recent decades, resulting in generally unsatisfactory outcomes. While randomized controlled trials (RCTs) are considered the gold standard for clinical research, they can be expensive and ethically challenging to conduct. Observational studies provide an alternative method, offering larger datasets covering longer periods, which can be more beneficial and feasible for certain research endeavors.

Machine Learning (ML) algorithms, unlike classical statistical methods, have the capability to process a vast number of variables, offering a personalized and dependable approach for healthcare providers in patient management. Recognizing the necessity for well-designed studies to identify optimal therapeutic strategies for neurocritical patients and acknowledging the limitations of existing guidelines, we aim to leverage ML programs to develop an advanced system capable of uncovering data patterns and linking them to potential outcomes.

The BLANDISH project focuses on patients with spontaneous intracerebral hemorrhage (sICH), a condition lacking proven beneficial treatment. By collecting and analyzing data from sICH patients admitted to neuroICU, the project aims to develop a supervised ML algorithm named BLANDISH.

This algorithm will stratify patients based on prognosis, identifying those at highest risk of death and secondary brain injuries. By guiding each patient towards the most targeted therapeutic strategy, the algorithm could help improve patient outcomes and assess the effectiveness of current clinical practices. Additionally, it may enable healthcare staff to better allocate resources and introduce individualized therapeutic programs based on precision medicine, potentially reducing hospitalization times and healthcare costs.

The initial step in developing the BLANDISH algorithm involves collecting clinical data, stored in a structured datalake, which serves as a data repository. This platform will gather information on the clinical course of sICH patients admitted to neuroICU. After data collection, the next steps include preprocessing, variable selection correlated with patient mortality, and algorithm training with input data and internal validation to control its behavior. External validation will follow, involving data collection from various clinical centers to assess the algorithm's reliability and generalization capacity. A multicenter observational clinical study will then be conducted to validate the BLANDISH algorithm, aiming to determine its impact on sICH patient outcomes. This final phase includes a survival study comparing patients in the experimental group (whose treatment is guided by BLANDISH) with those following standard clinical practice. The project aims to demonstrate the superiority of the ML approach over current guidelines, evaluating the accuracy and potential improvements in patient management across different care settings.

02

Conditions studied

  • Intracranial Hemorrhages
03

In context

Intracranial Hemorrhages

211 studies on the registry are indexed under Intracranial Hemorrhages; 62 are open to participants now.

This study's planned enrollment of 2,000 is above the median of 250 across 85 observational studies indexed under Intracranial Hemorrhages.

Browse Intracranial Hemorrhages studies →

Lead sponsor

IRCCS Ospedale San Raffaele is the lead sponsor of 37 studies on the registry; 29 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients affected by spontaneous Intracranial Hemorrhage.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who enter the NICU for acute spontaneous intracranial hemorrhage
  • Adult patients (≥ 18 years)
  • Sex: female, male, intersex

Exclusion criteria

Exclusion Criteria:

  • All patients affected by non-spontaneous ICH
  • Patients with sICH determined by brain tumor or
  • All patients affected by chronic ICH
  • Pregnant and puerperal women
  • Refusal to participate in the protocol
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
2,000 participants (estimated)
Target follow-up
14 Months
Patient registry
Yes

Groups and cohorts

  • Retrospective group

    Patients treated for spontaneous intracranial hemorrhage before March 13, 2024.

    Other: Treatment of spontaneous intracranial hemorrhage

  • Prospective group

    Patients treated for spontaneous intracranial hemorrhage after March 13, 2024.

    Other: Treatment of spontaneous intracranial hemorrhage

Interventions

  • OtherTreatment of spontaneous intracranial hemorrhage

    Data collection of therapeutic approach, including radiological, medical, surgical therapies.

06

What researchers measure

Primary outcomes

  1. Mortality

    Patients who die within 12 months after being treated for spontaneous intracranial hemorrhage

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2024 (actual). Primary completion is estimated for Dec 2028, 57 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2024
First posted
Mar 20, 2024
StartActual
Mar 13, 2024
Primary completionEst.
Dec 31, 2028
CompletionEst.
Jan 31, 2029
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • IRCCS Ospedale San Raffaele · Milan, Italy
Show 1 removed
  • IRCCS Ospedale San Raffaele · Milano, Italy
Nov 4, 2026
Contact
Study contact changed: t•••@hsr.it · •••8755→m•••@hsr.it · •••4464. See the current contact
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    1 site added, 1 site removed
    Show site
    • IRCCS Ospedale San Raffaele · Milan, Italy
    Show 1 removed
    • IRCCS Ospedale San Raffaele · Milano, Italy
    Contact Study contact changed: t•••@hsr.it · •••8755→m•••@hsr.it · •••4464. See the current contact
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06320132
Lead sponsor
IRCCS Ospedale San Raffaele
Responsible party
Francesca Guzzo (Principal Investigator, IRCCS Ospedale San Raffaele) — Principal investigator
First posted
Mar 20, 2024
Start date
Mar 13, 2024
Primary completion
Dec 31, 2028 (estimated)
Completion
Jan 31, 2029 (estimated)
Last update
Nov 4, 2026

Study contacts

Francesca Guzzo, MD
Contact
guzzo.francesca@hsr.it
+393470830669 ext. +390226433333
Marilena Marmiere, MD
Contact
marmiere.marilena@hsr.it
+393402124464 ext. +390226433333
Francesca Guzzo, MD
principal investigator · IRCCS Ospedale San Raffaele

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion